ABCL News and Press, AbCellera Biologics Inc. From 09/13/21

AbCellera (ABCL -5.7%) acquires TetraGenetics, a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins. It will be an all-cash transaction that includes an upfront payment, the potential for payments based on...

Acquisition expands AbCellera’s existing capabilities to unlock difficult-to-drug transmembrane proteins for antibody discovery programs AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today an...

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the BofA Securities  – Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021, at 9:00 a.m. Pacific Time. A live audio webcast of the presentation may ...

RenovoRx RNXT +46% after receiving new 510(k) clearance for RenovoCath Delivery System Mechel PAO (NYSE:MTL) +36%. Pliant Therapeutics PLRX +26% on positive PLN-74809 results in Phase 2a IPF study Adaptimmune Therapeutics ADAP +19% and Genentech collaborate to de...

Using the charts I show developing instability in the Nasdaq. Hedging isn't for everyone, but anyone can hold extra cash in their trading account. To be able to buy when everyone is selling can create a lot of alpha. That is what I am working for. I introduce the AI disru...

Shares of AbCellera Biologics (NASDAQ: ABCL) climbed 10.6% in June, according to data from S&P Global Market Intelligence . The biotech company published its second-quarter earnings release on Aug. 12 and held a conference call to discuss its results and outlook, and the...

AbCellera reported Q2 results on 08/12/21 which were well received by the market, sending shares up 15%. A remark by the CEO in the conference call, however, has me quite concerned. The company since IPO has indicated that royalties negotiated are between single digits and low double ...

Shares of biotechnology outfit AbCellera Biologics (NASDAQ: ABCL) were up 17.2% as of mid-session Friday following encouraging commentary within its second-quarter report. It certainly could have been worse. For the three-month span ending in June, AbCellera Biologics tu...

Gainers: GreenVision Acquisition (NASDAQ:GRNV) +154%. Evoke Pharma(NASDAQ:EVOK) +29%. LifeStance Health  (NASDAQ:LFST) +24%. CVD Equipment (NASDAQ:CVV) +23%. Pilgrim's Pride Corporation (NASDAQ:PPC) +21%. AbCellera Biologics (NASDAQ:ABCL) +21%. AeroCentury (NYSE:ACY) +19%. Sesen Bio (NAS...

Image source: The Motley Fool. AbCellera Biologics Inc. (NASDAQ: ABCL) Q2 2021 Earnings Call Aug 12, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: AbCellera Biologics Inc. (ABCL) Q2 2021 Earnings Call Transcript ...